NBTX

Nanobiotix S.A.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $27.90
52-Week Range: $14.78 – $57.14
Market Cap: $1.31B
P/E (TTM): —
EPS (TTM): -1.27
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -21.34%
Gross Margin: 100.00%
Operating Margin: -322.88%
Profit Margin: 0.00%
Current Ratio: 1.44
Debt/Equity: —
Total Debt: $106.61M
Free Cash Flow: $-32.78M
Revenue Growth: -79.20%
Earnings Growth: —
Enterprise Value: $1.30B

NBTX Income statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$30.06M	-$11.61M	$29.64M
Research & Development	$32.64M	$38.40M	$40.54M	$23.11M
Selling, General & Admin	$17.48M	$21.66M	$20.06M	$20.22M
Operating Expenses	$46.70M	$56.84M	$56.78M	$40.46M
Operating Income	-$46.70M	-$26.78M	-$68.39M	-$10.82M
EBITDA	-$49.70M	-$30.09M	-$58.33M	-$12.07M
Pretax Income	-$57.03M	-$39.58M	-$68.03M	-$23.96M
Income Tax	$10.00K	$120.00K	$101.00K	$3.00K
Net Income	-$57.04M	-$39.70M	-$68.13M	-$23.96M
Diluted EPS	-1.64	-1.08	-1.44	-0.50
Diluted Shares	34.78M	36.93M	47.27M	47.82M

NBTX Balance Sheet statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$41.39M	$75.28M	$49.74M	$52.75M
Receivables	$7.99M	$9.49M	$8.54M	$7.68M
Current Assets	$52.36M	$87.34M	$61.47M	$62.75M
Total Assets	$59.77M	$93.90M	$67.42M	$67.76M
Current Liabilities	$37.94M	$49.87M	$58.94M	$57.51M
Long-Term Debt	$44.04M	$41.66M	$43.01M	$89.12M
Total Debt	$53.17M	$50.56M	$50.90M	$95.32M
Total Liabilities	$86.81M	$95.74M	$133.12M	$152.24M
Retained Earnings	-$57.04M	-$39.70M	-$68.13M	-$23.96M
Shareholders' Equity	-$27.05M	-$1.84M	-$65.70M	-$84.48M
Working Capital	$14.42M	$37.47M	$2.53M	$5.24M
Net Debt	$6.25M	—	—	$39.47M

NBTX Cash Flow statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$37.10M	-$12.48M	-$19.55M	-$33.42M
Capital Expenditure	-$93.00K	-$337.00K	-$848.00K	-$546.00K
Free Cash Flow	-$37.20M	-$12.81M	-$20.40M	-$33.97M
Depreciation & Amortisation	$1.50M	$1.51M	$1.62M	$1.50M
Stock-Based Compensation	$3.17M	$3.22M	$4.30M	$3.54M
Investing Cash Flow	$138.00K	-$349.00K	-$955.00K	-$578.00K
Financing Cash Flow	-$5.65M	$46.77M	-$5.13M	$37.42M
Dividends Paid	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$42.62M	$33.95M	-$25.64M	$3.42M

NBTX Balance Sheet statement, quarterly periods, in EUR
EUR	Q4 2024	Q2 2025	Q4 2025
Cash & Equivalents	$49.74M	$28.82M	$52.75M
Receivables	$8.54M	$9.15M	$7.68M
Current Assets	$61.47M	$39.89M	$62.75M
Total Assets	$67.42M	$45.17M	$67.76M
Current Liabilities	$58.94M	$63.04M	$57.51M
Long-Term Debt	$43.01M	$44.12M	$89.12M
Total Debt	$50.90M	$51.24M	$95.32M
Total Liabilities	$133.12M	$114.13M	$152.24M
Retained Earnings	-$68.13M	-$5.38M	-$23.96M
Shareholders' Equity	-$65.70M	-$68.95M	-$84.48M
Working Capital	$2.53M	-$23.15M	$5.24M
Net Debt	—	$18.79M	$39.47M

Market Snapshot

About

Nanobiotix S.A. is a French clinical-stage biotechnology company developing NBTXR3, a proprietary radioenhancer nanotechnology designed to amplify radiation therapy for cancer treatment. The company focuses on oncology applications across multiple tumor types.